FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
MADISON, Wis., Jan. 5, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being held virtually on January 10-13, 2022. Boyd Clarke, Executive Chairman is scheduled to present via the live conference webcast on Wednesday, January 12 at 4:30 PM E.T.
Invited attendees of the Conference can access the virtual session for both live and on demand replay.
About FluGen:
FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases. The company’s lead candidate is M2SR, a supra-seasonal, live, single-replication, intranasal flu vaccine. Unlike standard of care flu vaccines, M2SR stimulates mucosal, humoral, and cellular immunity. In an unprecedented challenge trial, M2SR demonstrated protection against infection and illness across seven years of virus drift; and M2SR induces a durable antibody response with potential to cover an entire flu season and beyond. M2SR also has shown activity as a vaccine vector for other respiratory vaccines and infectious diseases, including a COVID-19/flu combination. For more information about FluGen, Inc., please visit http://www.FluGen.com/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/flugen-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301454061.html
SOURCE FluGen Inc
